Biotricity INC. (BTCY) — SEC Filings

Overview

Biotricity INC. (BTCY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 19, 2025: Biotricity Inc. (BTCY) is a medical technology company focused on biometric data monitoring solutions, particularly in the cardiac market. The company launched its Bioflux COM technology in April 2019, followed by Bioheart in 2021 and Biotres Cardiac Monitoring Device in 2022, expanding its sales to

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 6 bearish, 24 neutral, 3 mixed. The dominant filing sentiment for Biotricity INC. is neutral.

Filing Type Overview

Biotricity INC. (BTCY) has filed 2 S-1, 17 8-K, 6 10-Q, 2 10-K/A, 2 10-K, 1 10-Q/A, 1 SC 13G/A, 1 SC 13G, 1 DEF 14A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (33)

• Biotricity Secures $3M in Funding, Expands Cardiac AI Portfolio — S-1 · Dec 19, 2025 Risk: medium
  Biotricity Inc. (BTCY) is a medical technology company focused on biometric data monitoring solutions, particularly in the cardiac market. The company launched
• BioTricity Inc. Files 8-K on Financials — 8-K · Nov 18, 2025 Risk: low
  BioTricity Inc. filed an 8-K on November 18, 2025, reporting on its Results of Operations and Financial Condition as of November 14, 2025. The filing includes f
• Biotricity's Revenue Jumps 20% Amidst Persistent Going Concern Doubts — 10-Q · Nov 14, 2025 Risk: high
  BIOTRICITY INC. (BTCY) reported a significant increase in revenue for the six months ended September 30, 2025, reaching $7,759,788, up from $6,468,589 in the pr
• Biotricity Narrows Losses on Strong Revenue Growth — 10-Q · Aug 14, 2025 Risk: high
  BIOTRICITY INC. (BTCY) reported a significant increase in revenue for the three months ended June 30, 2025, reaching $3,873,993, up from $3,201,743 in the prior
• Biotricity Restates Equity, Reclassifies Preferred Stock — 10-K/A · Jul 18, 2025 Risk: medium
  BIOTRICITY INC.'s 10-K/A filing for the fiscal year ended March 31, 2025, primarily amends its previously filed 10-K, focusing on restatements related to equity
• Biotricity's Deficit Swells to $163.9M Amidst Capital Strain — 10-K · Jul 15, 2025 Risk: high
  BIOTRICITY INC. (BTCY) reported its 10-K for the fiscal year ended March 31, 2025, indicating continued financial challenges. The company's accumulated deficit,
• BioTricity Inc. Files 8-K on Financials — 8-K · Feb 24, 2025 Risk: low
  BioTricity Inc. filed an 8-K on February 24, 2025, reporting events as of February 20, 2025. The filing pertains to the company's results of operations, financi
• BioTricity Inc. Files 10-Q/A Amendment — 10-Q/A · Feb 20, 2025 Risk: medium
  BioTricity Inc. filed a 10-Q/A amendment on February 20, 2025, for the period ending December 31, 2024. The filing details financial information for the third q
• BioTricity Inc. Files Q3 2024 10-Q Report — 10-Q · Feb 19, 2025 Risk: medium
  BioTricity Inc. filed its 10-Q for the period ending December 31, 2024, reporting on its financial performance for the third quarter. The company, previously kn
• BioTricity Inc. Files 8-K on Financials — 8-K · Nov 20, 2024 Risk: low
  BioTricity Inc. filed an 8-K on November 20, 2024, reporting on its results of operations and financial condition as of November 15, 2024. The filing includes f
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• BioTricity Inc. Files Q2 2025 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  BioTricity Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the second quarter and the first six mon
• BioTricity Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 19, 2024 Risk: medium
  BioTricity Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company, formerly known as MetaSolutions, Inc.,
• BioTricity Inc. Files 8-K on Security Holder Vote Matters — 8-K · Aug 16, 2024 Risk: low
  BioTricity Inc. filed an 8-K on August 16, 2024, reporting on matters submitted to a vote of its security holders as of August 15, 2024. The filing does not con
• SC 13G Filing — SC 13G · Aug 8, 2024
• BioTricity Inc. Faces Delisting Concerns — 8-K · Aug 7, 2024 Risk: high
  BioTricity Inc. filed an 8-K on August 7, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was
• BioTricity Inc. Files Definitive Proxy Statement — DEF 14A · Aug 5, 2024 Risk: low
  BioTricity Inc. filed its definitive proxy statement on August 5, 2024, for its annual meeting of stockholders. The filing outlines proposals for the election o
• BioTricity Inc. Faces Listing Rule Concerns — 8-K · Aug 1, 2024 Risk: high
  BioTricity Inc. filed an 8-K on August 1, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of July 26, 2024.
• BioTricity Files 8-K for Equity Sale — 8-K · Jul 16, 2024 Risk: low
  On July 16, 2024, BioTricity Inc. filed an 8-K report detailing an unregistered sale of equity securities. The company issued 1,000,000 shares of common stock a
• BioTricity Inc. Files 8-K on Security Holder Votes — 8-K · Jul 12, 2024 Risk: low
  BioTricity Inc. filed an 8-K on July 12, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details ab
• BioTricity Inc. Files Annual Report Amendment — 10-K/A · Jun 28, 2024 Risk: medium
  BioTricity Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. The company, formerly known as MetaSolutions, Inc., i
• BioTricity Inc. Files 2024 10-K, Details Financial Structure — 10-K · Jun 27, 2024 Risk: medium
  BioTricity Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its operations in the surgical and medical instruments sector. The compan
• BioTricity Inc. Files 8-K for Material Agreement — 8-K · Jun 24, 2024 Risk: medium
  On June 21, 2024, BioTricity Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also re
• BioTricity Inc. Reports Unregistered Equity Sales — 8-K · Jun 7, 2024 Risk: medium
  On June 4, 2024, BioTricity Inc. reported the unregistered sale of equity securities. The company, incorporated in Nevada, issued shares under the 1934 Act, wit
• BIOTRICITY INC. Files Material Definitive Agreement 8-K — 8-K · May 28, 2024 Risk: medium
  On May 28, 2024, BIOTRICITY INC. filed an 8-K report detailing a material definitive agreement. The filing does not specify the nature of the agreement or any a
• BioTricity Reports Unregistered Equity Sales — 8-K · May 21, 2024 Risk: medium
  BioTricity Inc. filed an 8-K on May 21, 2024, reporting on unregistered sales of equity securities and other events. The filing indicates that on May 15, 2024,
• BioTricity Faces Nasdaq Delisting Warning — 8-K · May 3, 2024 Risk: high
  On April 30, 2024, BioTricity Inc. filed an 8-K report detailing its receipt of a notice from Nasdaq regarding its failure to meet the minimum bid price require
• BioTricity Inc. Faces Delisting Concerns — 8-K · Apr 23, 2024 Risk: high
  BioTricity Inc. filed an 8-K on April 23, 2024, to report a notice of delisting or failure to satisfy continued listing rules. The company, formerly known as Me
• BioTricity Inc. Files 8-K on Corporate Matters — 8-K · Apr 3, 2024 Risk: low
  BioTricity Inc. filed an 8-K on April 3, 2024, reporting on matters submitted to a vote of security holders and amendments to its articles of incorporation or b
• BioTricity Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 26, 2024 Risk: medium
  On March 25, 2024, BioTricity Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also r
• BioTricity Inc. Files S-1 Registration Statement — S-1 · Feb 28, 2024 Risk: medium
  BIOTRICITY INC. (BTCY) filed a IPO Registration (S-1) with the SEC on February 28, 2024. BioTricity Inc. filed an S-1 registration statement with the SEC. The c
• BioTricity Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 20, 2024 Risk: low
  BIOTRICITY INC. (BTCY) filed a Quarterly Report (10-Q) with the SEC on February 20, 2024. BioTricity Inc. filed a 10-Q report for the period ending December 31,
• BIOTRICITY INC. Receives Nasdaq Delisting Notice for Bid Price Non-Compliance — 8-K · Feb 2, 2024
  BIOTRICITY INC. (BTCY) announced on January 30, 2024, that it received a delisting notice from the Nasdaq Capital Market because its common stock failed to main

Risk Profile

Risk Assessment: Of BTCY's 30 recent filings, 7 were flagged as high-risk, 14 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Biotricity INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $7.76M
• Net Income: ($1.36M)
• EPS: ($0.057)
• Cash Position: $308,460

Key Executives

• Waqaas Al-Siddiq
• Ronald S. McIntyre
• Dr. Fareeha Siddiqui

Industry Context

Biotricity operates in the rapidly growing remote patient monitoring (RPM) market, particularly within cardiology. Key trends include increasing adoption of telehealth, demand for chronic disease management solutions, and advancements in AI for data analysis. The competitive landscape includes established medical device companies and emerging tech startups, all vying for market share through innovative solutions and regulatory approvals.

Top Tags

equity-sale (6) · financials (5) · 10-Q (5) · Medical Devices (4) · 8-k (3) · Healthcare Technology (3) · SEC Filing (3) · medical-devices (3) · corporate-governance (3) · material-agreement (3)

Key Numbers

• Gross proceeds from Series B Preferred Stock: $2,000,000 — Received on September 19, 2023, from an institutional investor
• Shares of Series B Preferred Stock issued: 220 — Issued at a purchase price of $9,090.91 per share
• Principal amount of unsecured convertible preferred note: $1,000,000 — Issued on October 31, 2023, to an investor
• Annual dividend rate for Series B Preferred Stock: 8% — Increases to 15% upon a Triggering Event
• Annual interest rate for unsecured convertible preferred note: 12% — Paid in cash monthly
• Initial conversion price for Series B Preferred Stock: $3.50 — Subject to adjustment based on stock performance or issuance
• Beneficial ownership limitation for Series B Preferred Stock conversion: 4.99% — Holders cannot exceed this percentage of outstanding Common Stock
• Maximum Common Stock issuance upon Series B conversion without shareholder approval: 19.9% — Based on outstanding Common Stock as of initial issuance date
• NIH Grant award received: $238,703 — Received in March 2023 for AI-Enabled real-time monitoring for stroke
• Patients diagnosed with afib benefited: 28,000 — Over the past two years through Biotricity's monitoring efforts
• Revenue: $7.76M — Increased by 19.9% for the six months ended September 30, 2025, from $6.47M in the prior year.
• Gross Profit: $6.30M — Increased by 30.6% for the six months ended September 30, 2025, from $4.82M in the prior year.
• Net Loss: ($1.36M) — Improved significantly from ($5.26M) in the prior year for the six months ended September 30, 2025.
• Accumulated Deficit: ($140.97M) — Increased from ($139.44M) at March 31, 2025, indicating continued losses.
• Working Capital Deficiency: ($18.08M) — Worsened from ($16.00M) at March 31, 2025, raising going concern doubts.

Related Companies

BTCR · NASDAQ:AAPL

Frequently Asked Questions